Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

6.9%

2 terminated/withdrawn out of 29 trials

Success Rate

92.9%

+6.4% vs industry average

Late-Stage Pipeline

21%

6 trials in Phase 3/4

Results Transparency

12%

3 of 26 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1

15(51.7%)

Phase 2

7(24.1%)

Phase 3

4(13.8%)

Phase 4

2(6.9%)

N/A

1(3.4%)

29Total

Phase 1(15)

Phase 2(7)

Phase 3(4)

Phase 4(2)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (29)

Showing 20 of 29 trials

NCT05287399Phase 1Completed

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASC61in Subjects With Advanced Solid Tumors

Role: lead

NCT06248008Phase 3Completed

A Study to Evaluate Safety of ASC40 Tablets in Patients With Moderate to Severe Acne Vulgaris

Role: lead

NCT06192264Phase 3Completed

A Study to Evaluate the Safety and Efficacy of ASC40 (Denifanstat) Tablets in the Treatment of Patients With Moderate to Severe Acne Vulgaris

Role: lead

NCT05104125Phase 2Completed

Study to Evaluate the Safety and Efficacy of ASC40 in Subjects With Moderate to Severe Acne Vulgaris

Role: lead

NCT04465890Phase 2Completed

A Phase II Study of Subcutaneously Injected PD-L1 Antibody ASC22 in Chronic Hepatitis B Patients

Role: lead

NCT05330143Phase 2Completed

Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV

Role: lead

NCT05718518Phase 1Completed

Study to Evaluate Safety, Tolerability, PK and the Food Effect on PK of ASC11/RTV Tablets in Healthy Subjects

Role: lead

NCT05596045Phase 1Withdrawn

Study to Evaluate Safety, Tolerability, Efficacy and Pharmacokinetics of ASC10 in Mild to Moderate COVID-19 Patients

Role: lead

NCT05118776Phase 3Active Not Recruiting

Study to Evaluate the Safety and Efficacy of ASC40 Tablets in Combination With Bevacizumab in Subjects With rGBM

Role: lead

NCT05107778Phase 2Completed

Study to Evaluate Safety and Efficacy of ASC42 Combined With ETV and PEG-IFN α-2a in Subjects With HBV

Role: lead

NCT05523141Phase 1Completed

Study to Evaluate Safety, Tolerability, Pharmacokinetics and the Food Effect on PK of ASC10 Tablets in Healthy Subjects

Role: lead

NCT04965337Phase 1Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of ASC42 in Chinese Healthy Subjects

Role: lead

NCT04261907Not ApplicableTerminated

Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus Infection

Role: collaborator

NCT04843449Phase 1Completed

Study to Evaluate the Effects of Itraconazole and Rifampin on the Pharmacokinetics of ASC40 in Healthy Subjects

Role: lead

NCT04527250Phase 1Completed

A Study of the Relative Bioavailability of ASC41 in Healthy Subjects

Role: lead

NCT03020082Phase 3Completed

Efficacy and Safety of Danoprevir/r + PR 12week Triple Therapy in Treatment Naive Non-Cirrhotic G1 CHC China III

Role: lead

NCT04547894Phase 1Completed

A Study of the Pharmacokinetics of ASC09F in Healthy Subjects

Role: lead

NCT04358523Phase 1Completed

A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy Volunteers

Role: lead

NCT03020095Phase 2Completed

Efficacy and Safety of Ravidasvir + Danoprevir/r 12-week Oral Therapy in Treatment-Naive Non Cirrhotic G1 CHC Taiwan

Role: lead

NCT03362814Phase 2Completed

Efficacy and Safety of Ravidasvir in Combination With Danoprevir/r and Ribavirin(RBV) in Treatment-naive, Non-cirrhotic, Chronic Hepatitis C Virus Genotype1 Infected Subjects.

Role: lead